DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
AGN-201904 is an investigational drug.
There have been 49 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Ocular Hypertension, Presbyopia, and Glaucoma, Open-Angle. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and Naurex, Inc, an affiliate of Allergan plc.
There are two US patents protecting this investigational drug and forty-three international patents.
Recent Clinical Trials for AGN-201904
|AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension||Allergan||Phase 1/Phase 2|
|Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia||Allergan||Phase 1/Phase 2|
|A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease||Allergan||Phase 1/Phase 2|
Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AGN-201904||Start Trial||Prodrugs of proton pump inhibitors||Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A)||Start Trial|
|AGN-201904||Start Trial||Process for preparing isomerically pure prodrugs of proton pump inhibitors||Allergan, Inc. (Irvine, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|